A new nationwide study has found substantial regional differences in sperm quality, with men in the highest-performing region recording almost double the total motile sperm count of those in the lowest-performing region.

Consumption of ultra-processed food (UPF) results in a distinct metabolic ‘signature’ in the blood, associated with potentially adverse health conditions, a new study by an international team of researchers finds.

Community science nonprofit Darwin's Ark is inviting researchers to access its pet genetics data, research tools and community science resources to advance pet and human health. Built through the participation of more than 25,000 cats, 50,000 dogs, 6,000 DNA sequences and more than 6 million survey responses, Darwin's Ark has created one of the world's largest community-powered pet research initiatives and is expanding opportunities for scientific collaboration.

Cellular and molecular interactions around tumors give insight into their structures and weaknesses, but measuring them has been expensive and slow. A Stanford Medicine AI platform flips the script.

Years of progress in reducing benzodiazepine prescribing among older Americans stalled after the onset of the COVID-19 pandemic, according to a decade-long national study from Columbia University Mailman School of Public Health and Columbia University Irving Medical Center.

A new study in JAMA Network Open followed 422 women who were already using combined oral contraceptives, tracking their eating patterns daily for 49 consecutive days. The goal: to examine whether binge-related eating changes depending on whether women are taking hormone-containing pills or hormone-free pills within the same cycle.

A new PNAS feature highlights the critical role of behavioral and decision sciences in U.S. governance. The publications demonstrate how psychological and economic research protects public health, consumer rights, and finances across government agencies including the FTC, SEC, and FDA. Case studies show how "invisible" scientific frameworks streamline medical drug reviews, combat digital deception, and model public health crises like the opioid epidemic, calling for stronger long-term ties between academic institutions and public policy. 

The U.S. Food and Drug Administration (FDA) has approved a new therapy regimen for patients with “double-positive” metastatic breast cancer based on results of the phase 3 PATINA study led by Otto Metzger, MD, Associate Medical Director of International Strategic Initiatives at Dana-Farber Cancer Institute. The PATINA trial demonstrated that the addition of the CDK 4/6 inhibitor palbociclib to standard therapy in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer resulted in a more than 15-month improvement in progression-free survival. The findings were reported in the New England Journal of Medicine and also presented at the San Antonio Breast Cancer Symposium in December 2024.